Journal of Shandong University (Health Sciences) ›› 2020, Vol. 58 ›› Issue (6): 53-59.doi: 10.6040/j.issn.1671-7554.0.2020.112

Previous Articles    

Correlation between thyroid hormonal levels and clinical characteristics of 142 women with breast cancer

GUO Tian1*, FU Yilin1*, GAO Ling1, SONG Yongfeng1, FU Guobin2, GENG Chong3, WANG Weibo2   

  1. 1. Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong Provincial Key Laboratory of Endocrinology and Lipid Metabolism, Institute of Endocrinology and Metabolism, Shandong Academy of Clinical Medicine, Jinan 250021, Shandong, China;
    2. Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China;
    3. Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Published:2022-09-27

PDF (PC)

29

Abstract: Objective To explore the relationship between clinical characteristics of female breast cancer and thyroid hormonal levels. Methods The clinical data of 142 female breast cancer patients were collected, including basic characteristics, tumor characteristics, thyroid function, and so on. The patients were classified into different groups according to age, menstrual status, tumor size, degree of metastasis, TNM stage, pathological grade, estrogen receptor, diabetes, surgery, chemotherapy and tumor markers. The differences in thyroid hormonal levels were statistically analyzed among the groups. Results (1) There was statistically significant difference in free triiodothyronine(FT3)level among the non-metastasis group, local lymph node metastasis group and distant metastasis group(F=11.565, P<0.001). The distant metastasis group had higher FT3 level than non-metastasis group ［(5.10±0.51)vs(4.67±0.45)pmol/L, P<0.001］ and local lymph node metastasis group ［(5.10±0.51)vs(4.58±0.49)pmol/L, P<0.001］. There was statistically significant difference in free thyroxine(FT4)level among the three groups(F=5.730, P<0.05). The non-metastasis group had higher FT4 level than local lymph node metastasis group ［(16.77±2.59)vs(15.26±2.15)pmol/L, P=0.001］ and distant metastasis group ［(16.77±2.59)vs(15.75±2.08)pmol/L, P=0.053］. When age, menstrual status, estrogen receptor, diabetes, surgery and chemotherapy were taken as covariates, there was significant difference in FT3 level among the three groups(F=6.810, P<0.05). The distant metastasis group had higher FT3 level than local lymph node metastasis group ［(5.10±0.12)vs(4.58±0.07)pmol/L, P<0.001］ and non-metastasis group ［(5.10±0.12)vs(4.67±0.06)pmol/L, P<0.001］, and local lymph node metastasis group had lower FT3 level than non-metastasis group ［(4.58±0.07)vs(4.67±0.06)pmol/L, P<0.001］. The was significant difference in FT4 level among the three groups(F=3.855, P<0.05). The local lymph node metastasis group had lower FT4 level than non-metastasis group ［(15.25±0.37)vs(16.52±0.32)pmol/L, P<0.001］ and distant metastasis group ［(15.25±0.37)vs )16.34±0.60)pmol/L, P<0.001］. (2) The surgical group had higher FT3 level than non-surgical group ［(4.86±0.59)vs(4.66±0.44)pmol/L, t=2.354, P<0.05］. (3) The chemotherapy group had higher FT3 level than non-chemotherapy group ［(4.95±0.50)vs(4.62±0.48)pmol/L, t=3.862, P<0.001］, but lower FT4 level ［(15.38±2.02)vs(16.49±2.57)pmol/L, t=-2.593, P<0.05］. Conclusion Thyroid hormones are associated with the metastasis of breast cancer. Both surgery and chemotherapy may affect the levels of thyroid hormones.

Key words: Thyroid hormones, Breast cancer, Metastasis, Triiodothyronine, Chemotherapy

CLC Number: 

  • R574
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1):1-12.
[3] Li H, Zheng RS, Zhang SW, et al. Incidence and mortality of female breast cancer in China, 2014[J]. Chin J Oncol, 2018, 40(3):166-171.
[4] Liu S, Yang L, Yuan Y, et al. Cancer incidence in Beijing, 2014[J]. Chin J Cancer Res, 2018, 30(1):13-20.
[5] Chen WQ, Li H, Sun KX, et al. Report of cancer incidence and mortality in China, 2014[J]. Chin J Oncol, 2018, 40(1):5-13.
[6] Kress E, Samarut J. Thyroid hormones and the control of cell proliferation or cell differentiation: paradox or duality?[J]. Mol Cell Endocrinol, 2009, 313(1-2):36-49.
[7] Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions form a new method of treatment, with illustrative cases[J]. Lacent, 1896, 2:104 -110.
[8] Angelousi A, Diamanti-Kandarakis E, Zapanti E, et al. Is there an association between thyroid function abnormalities and breast cancer?[J]. Arch Endocrinol Metab, 2017, 61(1):54-61.
[9] Shi XZ, Jin X, Xu P, et al. Relationship between breast cancer and levels of serum thyroid hormones and antibodies: a meta-analysis[J]. Asian Pac J Cancer Prev, 2014, 15(16):6643-6647.
[10] Wu CC, Yu YY, Yang HC, et al. Levothyroxine use and the risk of breast cancer: a nation-wide population-based case-control study[J]. Arch Gynecol Obstet, 2018, 298(2):389-396.
[11] Journy NMY, Bernier MO, Doody MM, et al. Hyperthyroidism, Hypothyroidism, and cause-specific mortality in a large cohort of women[J]. Thyroid, 2017, 27(8):1001-1010.
[12] Khan SR, Chaker L, Ruiter R, et al. Thyroid function and cancer risk: The rotterdam study[J]. J Clin Endocrinol Metab, 2016, 101(12):5030-5036.
[13] Brandt J, Borgquist S. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to risk of different breast cancer subgroups: a Malmö Diet and Cancer Study[J]. Cancer Causes Control, 2015, 26(8):1093-1104.
[14] Uyeturk U, Tatli AM, Gucuk S, et al. Risk factors for stage IV breast cancer at the time of presentation in Turkey[J]. Asian Pac J Cancer Prev, 2013, 14(12):7445-7449.
[15] Moeller LC, Führer D. Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective[J]. Endocr Relat Cancer, 2013, 20(2):19-29.
[16] Martínez-Iglesias O, García-Silva S, Regadera J. Hypothyroidism enhances tumor invasiveness and metastasis development[J]. PLoS One,2009,4(7):6428.
[17] 吴万敏, 张艳. 乳腺癌中THRβ1表达与甲状腺激素改变的临床研究[J]. 临床和实验医学杂志, 2014, 14(18):1513-1517. WU Wanmin, ZHANG Yan. Clinical study of the changes in expression of THRβ1 and thyroid hormone level in breast cancer [J]. Journal of Clinical and Experimental Medicine, 2014, 14(18):1513-1517.
[18] Glushakov RI, Proshin SN, Tapil’skaya NI. The incidence of breast tumor during experimental hyperthyroidism[J]. Bull Exp Biol Med, 2013, 156(2):245-247.
[19] Uzair ID, Conte Grand J, Flamini MI. Molecular actions of thyroid hormone on breast cancer cell migration and invasion via cortactin/N-WASP[J]. Front Endocrinol, 2019, 10:139. doi: 10.3389/fendo.2019.00139.
[20] Flamini MI, Uzair ID, Pennacchio GE, et al. Thyroid hormone controls breast cancer cell movement via integrin αV/β3/SRC/FAK/PI3-kinases[J]. Horm Cancer, 2017, 8(1):16-27.
[21] Tosovic A, Bondeson AG, Bondeson L, et al. T3 levels in relation to prognostic factors in breast cancer: a population-based prospective cohort study[J]. BMC cancer, 2014, 14:536. doi: 10.1186/1471-2407-14-536.
[22] Weingarten C, Jenudi Y, Tshuva RY, et al. The interplay between epithelial-mesenchymal transition(EMT)and the thyroid hormones-αvβ3 axis in ovarian cancer[J]. Horm Cancer, 2018, 9(1):22-32.
[23] Cohen K, Flint N, Shalev S, et al. Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αvβ3 integrin in myeloma cells[J]. Oncotarget, 2014, 5(15):6312-6322.
[24] Majkowska-Mynarczyk A, Kinalski M. The thyroid gland function assessment in women after mastectomy and chemotherapy during breast cancer therapy[J]. Endokrynol Pol, 2007, 58(5):397-402.
[25] 黄剑波, 金梁斌, 孔令泉,等. 乳腺癌患者治疗期间甲状腺功能的变化研究[J]. 重庆医科大学学报, 2014, 39(1):57-60. HUANG Jianbo, JIN Liangbin, KONG Lingquan, et al. Changes of thyroid functions among patients with breast cancer during therapy [J]. Journal of Chongqing Medical University, 2014, 39(1):57-60.
[26] 余欢, 李小平. 化疗对妇科恶性肿瘤患者甲状腺功能影响研究进展[J]. 中国妇产科临床杂志,2018, 19(6):560-563.
[27] Zhang L, Zhang F, Li Y, et al. Triiodothyronine promotes cell proliferation of breast cancer via modulating miR-204/amphiregulin[J]. Pathol Oncol Res, 2019, 25(2):653-658.
[28] Sar P, Peter R, Rath B, et al. 3, 3'5 Triiodo L thyronine induces apoptosis in human breast cancer MCF-7 cells, repressing SMP30 expression through negative thyroid response elements[J]. PLoS One, 2011, 6(6):20861.
[29] Barrera-Hernandez G, Park KS, Dace A, et al. Thyroid hormone-induced cell proliferation in GC cells is mediated by changes in G1 cyclin/cyclin-dependent kinase levels and activity[J]. Endocrinology, 1999, 140(11):5267-5274.
[30] Suhane S. Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells[J]. BiochemBiophys Res Commun, 2011, 414(1):73-78.
[31] Huang J, Jin L, Ji G, et al. Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine[J]. BMC Cancer, 2013, 13:334. doi: 10.1186/1471-2407-13-334.
[1] RUAN Xiangyan, CHENG Jiaojiao, DU Juan, GU Muqing. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30.
[2] LIN Yun, XIE Yanqiu. Fertility protection and preservation in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 42-46.
[3] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[4] Qifeng YANG,Ning ZHANG. Sentinel lymph node biopsy of breast cancer in the era of precision medicine [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 1-5.
[5] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[6] SHEN Xiaochang, SUN Yiqing, YAN Lei, ZHAO Xingbo. Expression of aryl hydrocarbon receptor nuclear translocator-like 2 in endometrial cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 74-80.
[7] ZHAO Tingting, QI Yana, ZHANG Ying, YUAN Bing, HAN Mingyong. Mouse breast cancer induces changes of the microenvironment in pre-metastatic lung tissue [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 24-29.
[8] ZHONG Lili, SHENG Ying, GUO Jianghong, YANG Shuangjian, HE Yijing. LncRNA-UCA1 effects invasion and metastasis of trophoblast cells by targeting miR-182-5p [J]. Journal of Shandong University (Health Sciences), 2022, 60(3): 76-82.
[9] Zhuxiu CHU,Wenjing ZHAO,Xiaoyan LI,Xiaoli KONG,Tingting MA,Liyu JIANG,Qifeng YANG. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139.
[10] WANG Zhe, LIU Yujie, MAO Qian, GUAN Peixia, BAO Qihan, LI Chengsheng, QIAO Xiaowei, PAN Qingzhong, WANG Suzhen. Evaluation of the efficacy of different regimens for early triple negative breast cancer based on the inverse probability of treatment weighting method [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 113-118.
[11] LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84.
[12] KONG Xue, LI Juan, DUAN Weili, SHI Shuang, LI Peilong, DU Lutao, MAO Haiting, WANG Chuanxin. Effects of lncRNA AC012073.1 on the migration and invasion of human breast cancer cells and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 70-78.
[13] GAO Jinmei, ZHANG Xianglian, LIU Tieju. Correlation between plasma D-dimer and metastasis in 109 cases of bladder cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 98-102.
[14] YOU Xueting, TIAN Xingsong. Analysis of clinicopathological characteristics of 3 514 cases of breast cancer over 9 years [J]. Journal of Shandong University (Health Sciences), 2021, 59(1): 49-54.
[15] WANG Yuyu, GAO Li, CHEN Shaohua. Association between cognitive impairment and thyroid function after acute ischemic stroke in 94 patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 56-61.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd